Drugs that contain Bempedoic Acid; Ezetimibe
1. Drug name - NEXLIZET
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7335799 | ESPERION THERAPS INC | Hydroxyl compounds and compositions for cholesterol management and related uses |
Dec, 2025
(3 years from now) | |
| EP1597223A2 | ESPERION THERAPS INC | Hydroxyl Compounds And Compositions For Cholesterol Management And Related Uses |
Dec, 2023
(1 year, 2 months from now) | |
| EP1597223B1 | ESPERION THERAPS INC | Hydroxyl Compounds And Compositions For Cholesterol Management And Related Uses |
Dec, 2023
(1 year, 2 months from now) | |
| EP2402300B1 | ESPERION THERAPS INC | Hydroxyl Compounds And Compositions For Cholesterol Management And Related Uses |
Dec, 2023
(1 year, 2 months from now) | |
| EP2402300A1 | ESPERION THERAPS INC | Hydroxyl Compounds And Compositions For Cholesterol Management And Related Uses |
Dec, 2023
(1 year, 2 months from now) | |
| EP2404890A1 | ESPERION THERAPS INC | Hydroxyl Compounds And Compositions For Cholesterol Management And Related Uses |
Dec, 2023
(1 year, 2 months from now) | |
| EP2404890B1 | ESPERION THERAPS INC | Hydroxyl Compounds And Compositions For Cholesterol Management And Related Uses |
Dec, 2023
(1 year, 2 months from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8497301 | ESPERION THERAPS INC | Hydroxyl compounds and compositions for cholesterol management and related uses |
Dec, 2023
(1 year, 2 months from now) | |
| US10118881 | ESPERION THERAPS INC | Hydroxyl compounds and compositions for cholesterol management and related uses |
Dec, 2023
(1 year, 2 months from now) | |
| US9000041 | ESPERION THERAPS INC | Hydroxyl compounds and compositions for cholesterol management and related uses |
Dec, 2023
(1 year, 2 months from now) | |
| US10941095 | ESPERION THERAPS INC | Hydroxyl compounds and compositions for cholesterol management and related uses |
Dec, 2023
(1 year, 2 months from now) | |
| US9624152 | ESPERION THERAPS INC | Hydroxyl compounds and compositions for cholesterol management and related uses |
Dec, 2023
(1 year, 2 months from now) | |
| US10912751 | ESPERION THERAPS INC | Fixed dose combinations and formulations comprising ETC1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease |
Mar, 2036
(13 years from now) | |
Treatment: Use of nexlizet as an adjunct to diet and maximally tolerated statin therapy to lower ldl-c in adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease; Use of nexlizet as an adjunct to diet and maximally tolerated statin therapy for inhibiting cholesterol synthesis to lower ldl-c in adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease; A method of treating heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease by decreasing the level of ldl-c using a fixed dose combination of 180 mg bempedoic acid and 10 mg ezetimibe
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 180MG;10MG | TABLET;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.